bioMérieux – Fourth-Quarter 2017 Business Review

• Excellent sales momentum in 2017 with 10.2% growth in sales, at constant exchange rates and scope of consolidation:
  
  • €2,288 million in sales
  • Up 8.8% as reported
• Growth underpinned by all strategic product lines, particularly BIOFIRE FILMARRAY^® which accounted for more than half of growth Group-wide
• Acceleration in growth in the EMEA and Asia-Pacific regions and steady doubledigit increase for the Americas
• bioMérieux expects contributive operating income before non-recurring items to be in line with its previous target of between €330 million and €345 million

Alexandre Mérieux, Chairman and Chief Executive Officer, said: "All told, 2017 was a year of remarkable growth for bioMérieux, driven by a portfolio of complementary technological solutions and a broad geographic footprint. We are particularly pleased with the performance of BIOFIRE, which confirms the success of syndromic diagnosis for infectious diseases, and with the faster-paced growth in industrial applications. These results reflect a valid business strategy that meets the needs of healthcare professionals through high medical value diagnostic solutions, and of the industry sector in order to protect consumer’s health."

Marcy l'Étoile, January 23, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the twelve months ended December 31, 2017.